KRAS and neoplasm: Mugarza et al. contend that KRAS-G12C inhibition leads to the upregulation of myc and the subsequent activation of the IFN signal, resulting in a decrease in the infiltration of immunosuppressive cells into the tumor, an enhancement of the infiltration and activation of cytotoxic T cells (CTLs), and an increase in antigen presentation.